Overview
Pharmaceutical company's Q4 revenue missed analyst expectations
Adjusted EBITDA loss more than doubled from a year ago
Company extended revenue-sharing agreement with RTW to June 2027
Outlook
Aquestive expects 2026 revenue between $46 mln and $50 mln
Company guides 2026 non-GAAP adjusted EBITDA loss to $35 mln-$30 mln
Aquestive plans to end FY2026 with $70 mln in cash
Result Drivers
REVENUE GROWTH - Revenue increased 10% in Q4 2025, driven by manufacturing and supply revenue from Suboxone and Ondif
R&D EXPENSES - R&D expenses decreased due to lower clinical trial costs for Anaphylm
HIGHER SG&A EXPENSES - Increased selling, general, and administrative expenses driven by legal and commercial costs for Anaphylm
Company press release: ID:nGNX2Z5l0g
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $13.02 mln | $13.28 mln (9 Analysts) |
Q4 Net Income | -$31.86 mln | ||
Q4 Adjusted EBITDA | Miss | -$27.33 mln | -$12.56 mln (2 Analysts) |
Q4 Income From Operations | -$28.84 mln | ||
Q4 Pretax Profit | -$31.86 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $9.00, about 118.4% above its March 3 closing price of $4.12
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments